VRG Therapeutics
VRG Therapeutics is a leading biopharma R&D company specializing in AI-driven drug discovery focused on designing and optimizing miniproteins for therapeutic purposes. Their proprietary platform combines AI-powered scaffold selection with advanced wet lab screening to enable rapid, cost-effective discovery of peptide-based pharmaceuticals and cell and gene therapy products. The company targets diseases with mechanisms unreachable by traditional methods, emphasizing autoimmune, chronic inflammatory, CNS, and oncology indications. Their miniproteins offer high stability, low immunogenicity, and exceptional selectivity and affinity, positioning VRG Therapeutics as an innovative player in next-generation biopharmaceuticals with a diverse and stable R&D pipeline.
VRG Therapeutics
VRG Therapeutics is a leading biopharma R&D company specializing in AI-driven drug discovery focused on designing and optimizing miniproteins for therapeutic purposes. Their proprietary platform combines AI-powered scaffold selection with advanced wet lab screening to enable rapid, cost-effective discovery of peptide-based pharmaceuticals and cell and gene therapy products. The company targets diseases with mechanisms unreachable by traditional methods, emphasizing autoimmune, chronic inflammatory, CNS, and oncology indications. Their miniproteins offer high stability, low immunogenicity, and exceptional selectivity and affinity, positioning VRG Therapeutics as an innovative player in next-generation biopharmaceuticals with a diverse and stable R&D pipeline.
TL;DR
Founded: 2023
Headquarters: Budapest, Hungary
Focus: AI-driven miniprotein therapeutics and cell & gene therapy
Notable asset: VRG-145 (late-preclinical migraine candidate)
Total disclosed funding: USD 5,453,907
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Developing next-generation peptide/miniprotein therapeutics and CGT products for diseases not amenable to traditional approaches.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Investors disclosed include Széchenyi Capital Fund Management and The Vascular Group; public summaries report the round on Aug 14, 2023.
Investor Signal
“VC-backed (Széchenyi Capital Fund Management and The Vascular Group disclosed as investors)”